Apogenix receives additional BMBF grant to develop APG101
APG101, a first-in-class, fully human protein is an inhibitor of the CD95 ligand (CD95L). The company will use the proceeds to develop APG101, and for the production of
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.